e-therapeutic signed a one year collaboration agreement with Novo Nordisk, a company specialising in diabetic care. Under the agreement, both the companies will use e-therapeutics’ Network-Driven Drug Discovery (NDD) method to find novel intervention strategies, biological pathways and compounds for testing that could possibly form the basis of novel therapies.
Moreover, Novo Nordisk has the option to license relevant IP generated under the collaboration, while reimbursement will be given for e-therapeutics’ work.
The companies are expected to use e-therapeutics’ proprietary NDD platform to identify potential novel biological mechanisms and therapeutic approaches for a specific area of type-2 diabetes, which exists in approximately 90% of the 425 million people with diabetes.
Dr Ray Barlow, CEO of e-therapeutics, said: “Our new collaboration with Novo Nordisk is the result of a systematic and rigorous business development exercise over the past year and we hope to announce a number of additional collaborations during the course of 2019.”